Selective Serotonin Reuptake Inhibitors: Perioperative Considerations

Introduction

• SSRIs are antidepressant medications that block the presynaptic reuptake of serotonin through inhibition of the serotonin transporter (SERT), increasing serotonin availability in the synaptic cleft.¹
• Increased synaptic serotonin enhances serotonergic transmission with mood-regulating neural pathways.

Clinical Uses

• Major depressive disorder (first-line therapy)
• Generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and obsessive-compulsive disorder,
• Premenstrual dysphoric disorder
• Off-label use, such as chronic pain syndromes and vasomotor symptoms

Commonly Used SSRIs

• Citalopram
• Escitalopram
• Fluoxetine
• Fluvoxamine
• Paroxetine
• Sertraline

Perioperative Considerations

Increased Bleeding Risk (Platelet Dysfunction)

• Platelets depend on serotonin uptake from the plasma to function properly, as they do not synthesize serotonin themselves. They do this by taking up serotonin via the SERT and storing it in dense granules.¹
• Upon vascular injury, platelets release serotonin to amplify aggregation and vasoconstriction, thereby facilitating the formation of a stable hemostatic plug. By inhibiting SERT, SSRIs prevent platelets from accumulating serotonin. Reduced platelet serotonin impairs platelet aggregation and primary hemostasis.²
• Epidemiologic studies and observational data have demonstrated an association between SSRI use and increased bleeding events such as gastrointestinal bleeding, surgical bleeding, and hemorrhagic complications. However, the absolute risk is low and varies with the patient’s comorbidities and concurrent medications.³

• SSRI use is associated with a modest increase in perioperative bleeding, most consistently reflected by higher rates of allogeneic red blood cell transfusion.⁴
• The highest increased bleeding risk has been reported in orthopedic surgery, particularly total hip and knee arthroplasty, where the use of serotonergic antidepressants correlates with higher transfusion requirements.⁵
• In various population-based analyses, antiplatelets, anticoagulants, and NSAIDs have been found to increase bleeding risk. Patients on SSRIs combined with warfarin or direct oral anticoagulants demonstrated higher rates of major bleeding.⁶
• With surgical case volumes increasing and the population aging, the overlap between SSRI use and high-risk surgeries such as spine, neurosurgery, cardiac, and trauma is expected to grow, making this an important anesthesiology topic.

• SSRI-induced platelet dysfunction may contribute to bleeding complications in perioperative and emergency settings. Due to the high volume of surgeries annually, a modest increase in bleeding risk can translate into a significant clinical burden.⁷
• Understanding the mechanism of SSRI-induced platelet dysfunction is critical for establishing a biological foundation for observed clinical patterns and informing risk-based perioperative management strategies.⁸

Risk of Serotonin Syndrome

• Serotonin syndrome results from excessive serotonergic activity, typically presenting with neuromuscular hyperactivity, autonomic instability, and altered mental status.⁷
• Perioperative triggers often involve interactions between SSRIs and serotonergic anesthetic agents (meperidine, tramadol, fentanyl, methylene blue, linezolid).⁸
• Diagnosis can be challenging intraoperatively, as symptoms may mimic malignant hyperthermia or neuroleptic malignant syndrome.
• Prevention relies on medication reconciliation, awareness of serotonergic drug combinations, and avoidance of high-risk agents when possible.

Cytochrome (CYP) P450 Interactions

• Several SSRIs inhibit CYP enzymes, most notably CYP2D6.
• Fluoxetine and paroxetine can reduce activation of prodrugs such as codeine, tramadol, and hydrocodone, lowering postoperative analgesic effectiveness.⁸
• CYP inhibition may also increase levels of perioperative drugs such as certain benzodiazepines or beta-blockers, impacting sedation and hemodynamic responses.

QT Interval Prolongation

• Citalopram and escitalopram have dose-dependent QT-prolonging effects.
• Risk increases when combined with other QT-prolonging agents (e.g., ondansetron and droperidol) or with electrolyte abnormalities.⁷
• High-risk patients may benefit from preoperative electrocardiogram review and cautious selection of adjunct medications.

Perioperative Management of SSRIs

• Most perioperative guidelines suggest continuing SSRIs for most surgeries, citing risks of withdrawal, relapse of depression, and exacerbation of anxiety disorders if stopped abruptly. Other institutions recommend tapering the SSRIs before high-bleeding risk surgeries, such as intracranial, spinal, major cardiac, or when SSRIs are combined with dual antiplatelet therapy.⁷
• Abrupt discontinuation of certain SSRIs, especially short half-life agents such as paroxetine and venlafaxine, can precipitate withdrawal symptoms leading to a more complicated postoperative assessment, including agitation, anxiety mimicking pain or delirium, and dizziness.
• A structured preoperative evaluation should identify:
  • Type and dose of SSRI
  • Concurrent antithrombotic agents
  • History of major bleeding
  • Nature and expected blood loss of the scheduled procedure
• In patients with a high bleeding risk, especially those on SSRIs plus antiplatelets or anticoagulants, it is important to:
  • Consider tapering SSRIs 2-3 weeks preoperatively
  • Reduce or discontinue non-essential antithrombotic
  • Consult the psychiatrist for individualized discontinuation plans
• Intraoperative management should include awareness of SSRI-related platelet dysfunction and readiness for bleeding or transfusion, especially in a large-volume surgery case.⁵
• Postoperatively, timing for resuming SSRIs should consider hemostatic stability, serotonin syndrome risk with various opioids, and psychiatric needs.

Anesthetic Considerations

• Abrupt discontinuation of SSRIs may cause withdrawal symptoms such as dizziness, anxiety, and agitation, as well as a potential relapse of depression, which can complicate postoperative recovery and lead to misinterpretation as pain, delirium, or inadequate anesthesia.⁷
• Intraoperative vigilance is critical with SSRI users, especially in surgeries that are expected to result in significant blood loss. Close hemostasis monitoring and early recognition of bleeding can help reduce the need for late transfusion.⁹
• Anesthesiologists must understand the serotonergic physiology in the perioperative setting regarding polypharmacy in psychiatric care and increasing recognition of serotonin syndrome risks.¹⁰
• SSRIs may influence the choice of analgesics, with special attention to avoid serotonergic opioids such as tramadol, meperidine, and high-dose fentanyl, in patients at risk for serotonin syndrome.¹⁰
• When considering interactions with CYP2D6-metabolized opioids and serotonin-modulated pain pathways, this can impact the postoperative pain control in SSRI patients. Thus, anesthesiologists need to anticipate variable analgesic responses.¹¹
• With further development and validation of a perioperative bleeding-risk stratification tool for patients on SSRIs, clinicians will be better able to make consistent, evidence-based decisions about continuation versus discontinuation.
• Given the limited studies on dose-dependent and SSRI-specific effects, it would be impactful to determine whether specific agents carry a higher bleeding risk or interact more strongly with antithrombotics.
• For the other emerging serotonergic agents, such as serotonin-norepinephrine reuptake inhibitors and multimodal antidepressants, there needs to be a thorough perioperative assessment since their bleeding risks may differ from traditional SSRIs.
• It is critical to address the balance between psychiatric stability and surgical bleeding risk, to help unify current clinical practice.